Literature DB >> 9308731

Hepatocyte growth factor and c-MET in benign and malignant peripheral nerve sheath tumors.

U N Rao1, E Sonmez-Alpan, G K Michalopoulos.   

Abstract

Hepatocyte growth factor (HGF), secreted by mesenchymal cells, has pleiotropic biological activities on several cell types. HGF and its receptor, the c-met proto-oncogene product (c-MET) have been implicated in the genesis and progression of several carcinomas and sarcomas. It has been suggested that MET/HGF autocrine signaling may contribute to tumorigenesis in sarcomas. HGF has been recently found to be a mitogen for rat Schwann cells and to be present in neurofibromas in NF1 patients. In this investigation, we assessed the immunoreactive patterns of HGF and MET in benign and malignant peripheral nerve sheath tumors (PNST) using archival formalin-fixed tissue. The standard avidin-biotin-peroxidase method was used. All benign tumors were negative with HGF. Eight cases of MPNST were positive with both HGF and MET. In some malignant PNST, positivity with both ligand and the receptor may be indicative of an autocrine mediated signal transduction and may implicate HGF/MET in tumor progression. Immunoreactivity with MET was strikingly greater in MPNST in contrast to benign PNST; this finding may prove to be helpful in distinguishing some histologically low-grade MPNST from cellular and atypical benign PNST.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9308731     DOI: 10.1016/s0046-8177(97)90060-5

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  20 in total

1.  Gene expression analysis identifies potential biomarkers of neurofibromatosis type 1 including adrenomedullin.

Authors:  Trent R Hummel; Walter J Jessen; Shyra J Miller; Lan Kluwe; Victor F Mautner; Margaret R Wallace; Conxi Lázaro; Grier P Page; Paul F Worley; Bruce J Aronow; Elizabeth K Schorry; Nancy Ratner
Journal:  Clin Cancer Res       Date:  2010-08-25       Impact factor: 12.531

2.  Overexpression of the hepatocyte growth factor (HGF) receptor (Met) and presence of a truncated and activated intracellular HGF receptor fragment in locally aggressive/malignant human musculoskeletal tumors.

Authors:  V Wallenius; M Hisaoka; K Helou; G Levan; N Mandahl; J M Meis-Kindblom; L G Kindblom; J O Jansson
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

3.  A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111).

Authors:  James I Geller; John P Perentesis; Xiaowei Liu; Charles G Minard; Rachel A Kudgus; Joel M Reid; Elizabeth Fox; Susan M Blaney; Brenda J Weigel
Journal:  Pediatr Blood Cancer       Date:  2017-04-27       Impact factor: 3.167

4.  Malignant peripheral nerve sheath tumour arising within neurofibroma. An immunohistochemical analysis in the comparison between benign and malignant components.

Authors:  T Watanabe; Y Oda; S Tamiya; K Masuda; M Tsuneyoshi
Journal:  J Clin Pathol       Date:  2001-08       Impact factor: 3.411

5.  c-MET expression in myofibroblasts: role in autocrine activation and prognostic significance in lung adenocarcinoma.

Authors:  M Tokunou; T Niki; K Eguchi; S Iba; H Tsuda; T Yamada; Y Matsuno; H Kondo; Y Saitoh; H Imamura; S Hirohashi
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

Review 6.  Liposarcoma: molecular targets and therapeutic implications.

Authors:  Kate Lynn J Bill; Lucia Casadei; Bethany C Prudner; Hans Iwenofu; Anne M Strohecker; Raphael E Pollock
Journal:  Cell Mol Life Sci       Date:  2016-05-12       Impact factor: 9.261

7.  Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors.

Authors:  Keila E Torres; Quan-Sheng Zhu; Katelynn Bill; Gonzalo Lopez; Markus P Ghadimi; Xianbiao Xie; Eric D Young; Juehui Liu; Theresa Nguyen; Svetlana Bolshakov; Roman Belousov; Suizhau Wang; Guy Lahat; Jun Liu; Belinda Hernandez; Alexander J Lazar; Dina Lev
Journal:  Clin Cancer Res       Date:  2011-05-03       Impact factor: 12.531

8.  Expression of Hepatocyte Growth Factor (HGF) and its Receptor (MET) in Medullary Carcinoma of the Thyroid.

Authors:  Mauro Papotti; Martina Olivero; Marco Volante; Francesco Negro; Maria Prat; Paolo M. Comoglio; Maria Flavia DiRenzo
Journal:  Endocr Pathol       Date:  2000       Impact factor: 3.943

9.  Trp53 haploinsufficiency modifies EGFR-driven peripheral nerve sheath tumorigenesis.

Authors:  Eric P Rahrmann; Branden S Moriarity; George M Otto; Adrienne L Watson; Kwangmin Choi; Margaret H Collins; Margaret Wallace; Beau R Webber; Colleen L Forster; Anthony E Rizzardi; Stephen C Schmechel; Nancy Ratner; David A Largaespada
Journal:  Am J Pathol       Date:  2014-05-13       Impact factor: 4.307

10.  Localization of Hepatocyte Growth Factor and Its Receptor met in Endocrine Cells and Related Tumors of the Gut and Pancreas: An Immunohistochemical Study.

Authors:  Stefano La Rosa; Silvia Uccella; Carlo Capella; Silvia Erba; Fausto Sessa
Journal:  Endocr Pathol       Date:  2000       Impact factor: 4.056

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.